Soleno Therapeutics, Inc.SLNONASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+88.2%
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

3Y CAGR
+88.2%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
6.7x
Strong expansion
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025167.73%
2024-177.05%
2023-20.01%
202225.17%
2021-10.09%
2020-45.17%
2019-48.72%
2018-17.42%
201726.29%
2016-31.06%